Pathology: non squamous - mNSCLC - L1 - Wild Type (WT);
non squamous - mNSCLC - L1 - Wild Type (WT) | |||||||
IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 | IMpower-150 (ABCP vs BPC WT), 2018 | IMpower-130 (WT), 2019 | IMpower-132 (WT), 0 | KEYNOTE-021, 2016 | KEYNOTE-189, 2018 | ||
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | 2 | T1 | T1 | ||||
atezolizumab plus pemetrexed and platin | 1 | T1 | |||||
atezolizumab plus carboplatin plus nab-paclitaxel | 1 | T1 | |||||
pembrolizumab plus SoC | 1 | T1 | |||||
pembrolizumab and pemetrexed plus platin | 1 | T1 | |||||
carboplatin plus nab-paclitaxel | 0 | T0 | |||||
pemetrexed plus platin | 0 | T0 | T0 | ||||
bevacizumab plus carboplatin and paclitaxel | 0 | T0 | T0 | ||||
placebo plus SoC | 0 | T0 |